New blood thinner could reduce clot risks in heart surgery recovery
NCT ID NCT06276010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a drug called nafamostat mesilate to the standard blood thinner heparin in 80 adults who need a heart-lung machine (ECMO) after heart surgery. The goal is to see which drug better prevents dangerous blood clots while causing fewer bleeding problems. Participants will be monitored for clot events and bleeding complications during their ECMO treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRACORPOREAL MEMBRANE OXYGENATION COMPLICATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital
RECRUITINGBeijing, Beijing Municipality, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may forecast life-threatening clots or bleeds on ECMO
- Portable MRI could spot brain injury in children on life support
- ECMO Patients' hidden infection risk under the microscope
- ECMO breakthrough? major trial aims to cut deadly complications
- New study aims to uncover why ECMO patients bleed
- ECMO blood thinner showdown: which drug wins?